They showed that a treatment with cisplatin selectively depleted these OCT3/4-positive cancer stem cells (by apoptosis), demonstrating in vivo why DNA-damaging agents are particularly effective in TGCTs compared to other somatic cancers. The gene discussed is POU5F1; the disease is cancer.